Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
PURPOSE: Phase II trial to study the effectiveness of flutamide and finasteride in treating prostate cancer patients with high PSA levels who were previously treated with radiation therapy or radical prostatectomy.
Sexual Dysfunction and Infertility
Other: quality-of-life assessment
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer|
- PSA levels [ Time Frame: 1 year post treatment ] [ Designated as safety issue: No ]
- QOL issues associated with treatment protocol [ Time Frame: 3 & 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||May 1998|
|Estimated Study Completion Date:||July 2017|
|Primary Completion Date:||May 2002 (Final data collection date for primary outcome measure)|
Experimental: Hormone Therapy
Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
5 mg/d PODrug: flutamide
250 mg PO tidOther: quality-of-life assessment
Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
- Determine the efficacy of finasteride and flutamide in suppressing prostate specific antigen (PSA) levels in patients with elevated PSA after definitive radiation therapy or radical prostatectomy for prostate cancer.
- Assess sexual function and other quality of life issues during this therapy.
- Estimate the response to flutamide withdrawal in this group of patients who have not had a major reduction in circulating testosterone levels.
- Measure the response rate to further hormonal manipulation with combined androgen blockade after the failure of this therapy.
- Obtain data that may predict more aggressive disease.
OUTLINE: This is a multicenter study.
Patients receive finasteride and flutamide by mouth three times a day. Patients experiencing recurrence or a greater than 4 nu/mL (above 50%) increase in PSA level will discontinue flutamide treatments. Otherwise, patients continue therapy in the absence of unacceptable toxicity or disease progression.
Quality of life is assessed prior to therapy and at 3 and 6 months.
Patients are followed every 3 months for one year and every 6 months thereafter.
PROJECTED ACCRUAL: This study will accrue 100 patients over 2 years.